Introduction

Severe eosinophilic asthma has been associated with Th2 airway inflammation and elevated proinflammatory cytokines and chemokines, such as IL-5. Precision therapies have recently been shown to improve asthma symptoms with a steroid-sparing effect. Two such therapies, Benralizumab and Mepolizumab, humanized IgG antibodies directed against the IL-5 receptor and IL-5, have been approved for severe eosinophilic asthma.

Methods

Here we used a differential proteomic approach to analyse serum from patients with severe eosinophilic asthma treated with Benralizumab and Mepolizumab in a search for differential molecular modifications responsible of their effects. Enrichment analysis of differential proteins was performed for the two treatments.

Results and discussion

After one month of Benralizumab treatment we detected up-regulation of certain protein species of the antioxidant ceruloplasmin. To investigate oxidative stress, we performed redox proteomics which detected lower oxidative burst after one month of Benralizumab treatment than in the pre-treatment phase or after one month of Mepolizumab therapy.

中文翻译：

---

美泊珠单抗和贝那珠单抗治疗的重度嗜酸性哮喘患者中铜蓝蛋白和氧化应激

介绍

严重的嗜酸性粒细胞性哮喘与Th2气道炎症，促炎性细胞因子和趋化因子（例如IL-5）升高有关。最近，精确疗法已显示出可通过类固醇保护作用改善哮喘症状。两种此类疗法，贝那珠单抗和美泊利单抗，针对IL-5受体和IL-5的人源化IgG抗体，已被批准用于重度嗜酸性哮喘。

方法

在这里，我们使用差异蛋白质组学方法分析了使用Benralizumab和Mepolizumab治疗的重度嗜酸性哮喘患者的血清，以寻找引起其影响的差异分子修饰。对两种处理进行差异蛋白的富集分析。

结果和讨论

贝那利珠单抗治疗一个月后，我们检测到抗氧化剂铜蓝蛋白的某些蛋白质上调。为了研究氧化应激，我们进行了氧化还原蛋白质组学研究，该方法检测到在Benralizumab治疗一个月后比在治疗前或Mepolizumab治疗一个月后的氧化爆发更低。